<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p172" style="overflow: hidden; position: relative; background-color: white; width: 1210px; height: 935px;">
<style class="shared-css" type="text/css" >
.t {
	transform-origin: bottom left;
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
	line-height: 1.5;
}
.text-container {
	white-space: pre;
}
@supports (-webkit-touch-callout: none) {
	.text-container {
		white-space: normal;
	}
}
</style>
<style type="text/css" >

#t1_172{left:35px;bottom:24px;letter-spacing:-0.34px;word-spacing:0.13px;}
#t2_172{left:306px;bottom:30px;}
#t3_172{left:313px;bottom:24px;letter-spacing:0.16px;}
#t4_172{left:346px;bottom:30px;}
#t5_172{left:351px;bottom:24px;letter-spacing:-0.16px;word-spacing:-0.22px;}
#t6_172{left:517px;bottom:30px;}
#t7_172{left:524px;bottom:24px;letter-spacing:-0.28px;word-spacing:-0.09px;}
#t8_172{left:288px;bottom:860px;letter-spacing:0.11px;word-spacing:-0.55px;}
#t9_172{left:288px;bottom:829px;letter-spacing:0.27px;word-spacing:-0.69px;}
#ta_172{left:1115px;bottom:27px;letter-spacing:0.23px;}
#tb_172{left:35px;bottom:777px;letter-spacing:0.11px;word-spacing:-1.16px;}
#tc_172{left:35px;bottom:754px;letter-spacing:0.1px;word-spacing:0.08px;}
#td_172{left:496px;bottom:761px;letter-spacing:-0.01px;}
#te_172{left:519px;bottom:754px;letter-spacing:0.45px;}
#tf_172{left:35px;bottom:731px;letter-spacing:0.11px;word-spacing:-0.2px;}
#tg_172{left:35px;bottom:707px;letter-spacing:0.19px;word-spacing:-0.57px;}
#th_172{left:35px;bottom:684px;letter-spacing:0.08px;word-spacing:0.1px;}
#ti_172{left:35px;bottom:661px;letter-spacing:0.14px;word-spacing:0.05px;}
#tj_172{left:35px;bottom:638px;letter-spacing:0.17px;word-spacing:0.05px;}
#tk_172{left:175px;bottom:638px;letter-spacing:0.19px;word-spacing:0.01px;}
#tl_172{left:491px;bottom:638px;letter-spacing:0.1px;word-spacing:0.09px;}
#tm_172{left:35px;bottom:614px;letter-spacing:0.13px;word-spacing:0.06px;}
#tn_172{left:35px;bottom:575px;letter-spacing:0.07px;word-spacing:0.12px;}
#to_172{left:35px;bottom:552px;letter-spacing:0.02px;word-spacing:-1.07px;}
#tp_172{left:35px;bottom:529px;letter-spacing:0.14px;word-spacing:0.05px;}
#tq_172{left:35px;bottom:506px;letter-spacing:0.03px;word-spacing:0.15px;}
#tr_172{left:143px;bottom:513px;letter-spacing:-0.01px;}
#ts_172{left:166px;bottom:506px;letter-spacing:0.2px;word-spacing:-0.02px;}
#tt_172{left:35px;bottom:482px;word-spacing:-1.05px;}
#tu_172{left:104px;bottom:482px;}
#tv_172{left:120px;bottom:482px;letter-spacing:0.18px;word-spacing:-0.12px;}
#tw_172{left:35px;bottom:459px;letter-spacing:0.14px;word-spacing:0.05px;}
#tx_172{left:35px;bottom:436px;letter-spacing:0.07px;word-spacing:0.12px;}
#ty_172{left:304px;bottom:444px;letter-spacing:0.61px;}
#tz_172{left:319px;bottom:436px;letter-spacing:0.06px;word-spacing:0.12px;}
#t10_172{left:494px;bottom:444px;letter-spacing:-0.01px;}
#t11_172{left:517px;bottom:436px;letter-spacing:0.21px;word-spacing:-0.02px;}
#t12_172{left:35px;bottom:413px;letter-spacing:0.05px;word-spacing:-1.1px;}
#t13_172{left:35px;bottom:390px;letter-spacing:0.01px;word-spacing:0.17px;}
#t14_172{left:35px;bottom:349px;letter-spacing:0.13px;word-spacing:0.06px;}
#t15_172{left:35px;bottom:326px;letter-spacing:0.09px;word-spacing:0.09px;}
#t16_172{left:35px;bottom:303px;letter-spacing:0.09px;word-spacing:0.1px;}
#t17_172{left:35px;bottom:280px;}
#t18_172{left:45px;bottom:287px;letter-spacing:0.61px;}
#t19_172{left:60px;bottom:280px;letter-spacing:0.07px;word-spacing:0.12px;}
#t1a_172{left:392px;bottom:287px;letter-spacing:-0.01px;}
#t1b_172{left:416px;bottom:280px;letter-spacing:0.06px;word-spacing:0.12px;}
#t1c_172{left:35px;bottom:256px;letter-spacing:-0.03px;word-spacing:-0.4px;}
#t1d_172{left:185px;bottom:264px;letter-spacing:-0.01px;}
#t1e_172{left:207px;bottom:256px;letter-spacing:0.17px;word-spacing:-0.6px;}
#t1f_172{left:35px;bottom:233px;letter-spacing:0.06px;word-spacing:0.13px;}
#t1g_172{left:35px;bottom:210px;letter-spacing:0.09px;word-spacing:-0.6px;}
#t1h_172{left:35px;bottom:187px;letter-spacing:0.15px;word-spacing:0.04px;}
#t1i_172{left:35px;bottom:148px;letter-spacing:0.06px;word-spacing:-0.8px;}
#t1j_172{left:35px;bottom:124px;letter-spacing:0.01px;word-spacing:-0.69px;}
#t1k_172{left:582px;bottom:132px;letter-spacing:-0.62px;}
#t1l_172{left:35px;bottom:101px;letter-spacing:0.07px;word-spacing:-1.12px;}
#t1m_172{left:496px;bottom:109px;letter-spacing:-0.01px;}
#t1n_172{left:518px;bottom:101px;letter-spacing:0.01px;}
#t1o_172{left:35px;bottom:78px;letter-spacing:0.12px;word-spacing:-0.29px;}
#t1p_172{left:35px;bottom:55px;letter-spacing:0.05px;word-spacing:0.14px;}
#t1q_172{left:618px;bottom:777px;letter-spacing:0.1px;word-spacing:0.09px;}
#t1r_172{left:618px;bottom:754px;letter-spacing:0.11px;word-spacing:-0.61px;}
#t1s_172{left:618px;bottom:731px;letter-spacing:0.07px;word-spacing:0.11px;}
#t1t_172{left:820px;bottom:738px;letter-spacing:0.1px;}
#t1u_172{left:865px;bottom:731px;letter-spacing:0.17px;word-spacing:0.01px;}
#t1v_172{left:618px;bottom:707px;letter-spacing:0.1px;word-spacing:-0.97px;}
#t1w_172{left:618px;bottom:684px;letter-spacing:0.12px;word-spacing:0.07px;}
#t1x_172{left:834px;bottom:692px;letter-spacing:-0.01px;}
#t1y_172{left:852px;bottom:684px;}
#t1z_172{left:647px;bottom:644px;}
#t20_172{left:673px;bottom:644px;letter-spacing:0.15px;word-spacing:0.03px;}
#t21_172{left:673px;bottom:621px;letter-spacing:0.15px;word-spacing:0.03px;}
#t22_172{left:647px;bottom:596px;}
#t23_172{left:673px;bottom:596px;letter-spacing:0.03px;word-spacing:-1.08px;}
#t24_172{left:673px;bottom:573px;letter-spacing:0.05px;word-spacing:-0.96px;}
#t25_172{left:673px;bottom:550px;letter-spacing:0.11px;word-spacing:0.08px;}
#t26_172{left:673px;bottom:526px;letter-spacing:0.04px;word-spacing:0.15px;}
#t27_172{left:673px;bottom:503px;letter-spacing:0.18px;word-spacing:0.01px;}
#t28_172{left:673px;bottom:480px;letter-spacing:0.05px;word-spacing:0.16px;}
#t29_172{left:618px;bottom:440px;letter-spacing:0.14px;word-spacing:0.05px;}
#t2a_172{left:618px;bottom:416px;letter-spacing:0.15px;word-spacing:0.03px;}
#t2b_172{left:673px;bottom:376px;letter-spacing:0.25px;word-spacing:-0.06px;}
#t2c_172{left:673px;bottom:354px;letter-spacing:0.35px;word-spacing:-0.16px;}
#t2d_172{left:733px;bottom:354px;letter-spacing:0.17px;word-spacing:0.02px;}
#t2e_172{left:673px;bottom:332px;letter-spacing:0.15px;word-spacing:0.04px;}
#t2f_172{left:673px;bottom:310px;letter-spacing:0.17px;word-spacing:0.02px;}
#t2g_172{left:776px;bottom:310px;letter-spacing:0.23px;word-spacing:-0.04px;}
#t2h_172{left:673px;bottom:288px;letter-spacing:0.27px;word-spacing:-0.09px;}
#t2i_172{left:618px;bottom:250px;letter-spacing:0.09px;word-spacing:-0.59px;}
#t2j_172{left:618px;bottom:227px;letter-spacing:0.13px;word-spacing:0.06px;}
#t2k_172{left:618px;bottom:204px;letter-spacing:0.25px;word-spacing:-1.3px;}
#t2l_172{left:755px;bottom:211px;letter-spacing:0.61px;}
#t2m_172{left:770px;bottom:204px;letter-spacing:0.05px;word-spacing:0.14px;}
#t2n_172{left:1104px;bottom:211px;letter-spacing:-0.01px;}
#t2o_172{left:1127px;bottom:204px;letter-spacing:-0.06px;}
#t2p_172{left:618px;bottom:181px;letter-spacing:0.04px;word-spacing:0.14px;}
#t2q_172{left:618px;bottom:157px;letter-spacing:0.14px;word-spacing:0.05px;}
#t2r_172{left:618px;bottom:134px;letter-spacing:0.02px;word-spacing:0.16px;}
#t2s_172{left:618px;bottom:111px;letter-spacing:-0.11px;word-spacing:0.31px;}
#t2t_172{left:677px;bottom:118px;letter-spacing:0.61px;}
#t2u_172{left:692px;bottom:111px;letter-spacing:0.06px;word-spacing:0.12px;}
#t2v_172{left:911px;bottom:118px;letter-spacing:-0.01px;}
#t2w_172{left:23px;bottom:915px;letter-spacing:-0.14px;}

.s0_172{font-size:10px;font-family:ArialMT_5tg;color:#000;}
.s1_172{font-size:6px;font-family:ArialMT_5tg;color:#000;}
.s2_172{font-size:28px;font-family:Arial-BoldMT_5te;color:#000;}
.s3_172{font-size:17px;font-family:Arial-BoldMT_5te;color:#000;}
.s4_172{font-size:17px;font-family:ArialMT_5tg;color:#000;}
.s5_172{font-size:11px;font-family:ArialMT_5tg;color:#000;}
.s6_172{font-size:17px;font-family:Arial-ItalicMT_kb;color:#000;}
.s7_172{font-size:17px;font-family:ArialMT_k0;color:#000;}
.s8_172{font-size:17px;font-family:SymbolMT_ka;color:#000;}
.s9_172{font-size:11px;font-family:Helvetica, Arial, sans-serif;color:#000;}
</style>
<style id="fonts172" type="text/css" >

@font-face {
	font-family: Arial-BoldMT_5te;
	src: url("fonts/Arial-BoldMT_5te.woff") format("woff");
}

@font-face {
	font-family: Arial-ItalicMT_kb;
	src: url("fonts/Arial-ItalicMT_kb.woff") format("woff");
}

@font-face {
	font-family: ArialMT_5tg;
	src: url("fonts/ArialMT_5tg.woff") format("woff");
}

@font-face {
	font-family: ArialMT_k0;
	src: url("fonts/ArialMT_k0.woff") format("woff");
}

@font-face {
	font-family: SymbolMT_ka;
	src: url("fonts/SymbolMT_ka.woff") format("woff");
}

</style>
<div id="pg172Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg172" style="-webkit-user-select: none;"><object width="1210" height="935" data="172/172.svg" type="image/svg+xml" id="pdf172" style="width:1210px; height:935px; z-index: 0;"></object></div>
<div class="text-container"><span id="t1_172" class="t s0_172">Version 4.2024 © 2024 National Comprehensive Cancer Network </span>
<span id="t2_172" class="t s1_172">© </span>
<span id="t3_172" class="t s0_172">(NCCN </span>
<span id="t4_172" class="t s1_172">© </span>
<span id="t5_172" class="t s0_172">), All rights reserved. NCCN Guidelines </span>
<span id="t6_172" class="t s1_172">® </span>
<span id="t7_172" class="t s0_172">and this illustration may not be reproduced in any form without the express written permission of NCCN. </span>
<span id="t8_172" class="t s2_172">NCCN Guidelines Version 4.2024 </span>
<span id="t9_172" class="t s2_172">Head and Neck Cancers </span>
<span id="ta_172" class="t s3_172">MS-31 </span>
<span id="tb_172" class="t s4_172">nodes, since extranodal extension is difficult to accurately capture through </span>
<span id="tc_172" class="t s4_172">the imaging workup that is routinely done for clinical staging. </span>
<span id="td_172" class="t s5_172">426 </span>
<span id="te_172" class="t s4_172">The </span>
<span id="tf_172" class="t s4_172">treatment algorithm for p16-negative disease is divided into three staging </span>
<span id="tg_172" class="t s4_172">categories: 1) T1–2, N0–1; 2) T3–4a, N0–1; and 3) any T, N2–3. Of note, </span>
<span id="th_172" class="t s4_172">the following categories are treated as advanced cancer: T4b, any N; </span>
<span id="ti_172" class="t s4_172">unresectable nodal disease; unfit for surgery; or M1 disease at initial </span>
<span id="tj_172" class="t s4_172">presentation (see </span><span id="tk_172" class="t s6_172">Very Advanced Head and Neck Cancers </span><span id="tl_172" class="t s4_172">in the NCCN </span>
<span id="tm_172" class="t s4_172">Guidelines for Head and Neck Cancers). </span>
<span id="tn_172" class="t s4_172">A clinical staging system for p16-positive oropharyngeal cancer was </span>
<span id="to_172" class="t s4_172">developed using data from 1907 patients with non-metastatic HPV-positive </span>
<span id="tp_172" class="t s4_172">oropharyngeal cancer from seven cancer centers in Europe and the </span>
<span id="tq_172" class="t s4_172">United States. </span>
<span id="tr_172" class="t s5_172">427 </span>
<span id="ts_172" class="t s4_172">OS did not significantly differ between T4a and T4b </span>
<span id="tt_172" class="t s4_172">disease (</span><span id="tu_172" class="t s6_172">P </span><span id="tv_172" class="t s4_172">= .41). Therefore, these were collapsed into one T4 category. </span>
<span id="tw_172" class="t s4_172">Five-year OS rates did not significantly differ in patients with N1, N2a, or </span>
<span id="tx_172" class="t s4_172">N2b disease, based on the AJCC 7 </span>
<span id="ty_172" class="t s5_172">th </span>
<span id="tz_172" class="t s4_172">edition N classification, </span>
<span id="t10_172" class="t s5_172">390 </span>
<span id="t11_172" class="t s4_172">so the </span>
<span id="t12_172" class="t s4_172">study investigators reasoned that these patients could be grouped into one </span>
<span id="t13_172" class="t s7_172">category (ie, at least one ipsilateral metastatic node ≤6 cm). </span>
<span id="t14_172" class="t s4_172">An analysis of 704 patients with resected p16-positive oropharyngeal </span>
<span id="t15_172" class="t s4_172">squamous cell carcinoma from five cancer centers showed that the N- </span>
<span id="t16_172" class="t s4_172">classification system for oropharyngeal cancer that was described in the </span>
<span id="t17_172" class="t s4_172">7 </span>
<span id="t18_172" class="t s5_172">th </span>
<span id="t19_172" class="t s4_172">edition of the AJCC Cancer Staging Manual </span>
<span id="t1a_172" class="t s5_172">390 </span>
<span id="t1b_172" class="t s4_172">was not significantly </span>
<span id="t1c_172" class="t s4_172">associated with OS. </span>
<span id="t1d_172" class="t s5_172">428 </span>
<span id="t1e_172" class="t s4_172">However, patients with four or fewer pathologically </span>
<span id="t1f_172" class="t s4_172">confirmed metastatic nodes had a higher 5-year OS rate, compared to </span>
<span id="t1g_172" class="t s4_172">patients with five or more pathologically confirmed metastatic nodes (89% </span>
<span id="t1h_172" class="t s4_172">vs. 71%, respectively). </span>
<span id="t1i_172" class="t s4_172">The recommendations for p16 (HPV)-positive oropharyngeal cancer in the </span>
<span id="t1j_172" class="t s4_172">NCCN Guidelines for Head and Neck Cancers accommodate the AJCC 8 </span>
<span id="t1k_172" class="t s5_172">th </span>
<span id="t1l_172" class="t s4_172">edition staging system for p16-positive oropharyngeal cancer. </span>
<span id="t1m_172" class="t s5_172">391 </span>
<span id="t1n_172" class="t s4_172">However, </span>
<span id="t1o_172" class="t s4_172">differences in recommendations between p16-negative disease and p16- </span>
<span id="t1p_172" class="t s4_172">positive disease are relatively modest, since the staging system is based </span>
<span id="t1q_172" class="t s4_172">on prognostic models and is not based on prospective data from clinical </span>
<span id="t1r_172" class="t s4_172">trials that guide clinical decision-making. Based on differences in features </span>
<span id="t1s_172" class="t s4_172">associated with prognosis, </span>
<span id="t1t_172" class="t s5_172">427,428 </span>
<span id="t1u_172" class="t s4_172">the staging criteria for p16-positive </span>
<span id="t1v_172" class="t s4_172">oropharyngeal cancer differs from staging for p16-negative oropharyngeal </span>
<span id="t1w_172" class="t s4_172">cancer in the following ways </span>
<span id="t1x_172" class="t s5_172">391 </span>
<span id="t1y_172" class="t s4_172">: </span>
<span id="t1z_172" class="t s8_172">• </span><span id="t20_172" class="t s4_172">T4b disease has been removed from the staging criteria for </span>
<span id="t21_172" class="t s4_172">defining the primary tumor. </span>
<span id="t22_172" class="t s8_172">• </span><span id="t23_172" class="t s4_172">Criteria for defining nodal involvement (both clinical and pathologic) </span>
<span id="t24_172" class="t s4_172">have been simplified for p16-positive disease. Clinical N staging for </span>
<span id="t25_172" class="t s4_172">p16-positive oropharyngeal cancer is based on lymph node size </span>
<span id="t26_172" class="t s4_172">and laterality, while pathologic N staging is based on number of </span>
<span id="t27_172" class="t s4_172">lymph nodes. Further, pN3 disease has been removed for </span>
<span id="t28_172" class="t s4_172">pathologic N. </span>
<span id="t29_172" class="t s4_172">The treatment algorithms for p16-positive disease have been divided by </span>
<span id="t2a_172" class="t s4_172">the panel into four staging categories: </span>
<span id="t2b_172" class="t s4_172">1) cT1–2, cN0 </span>
<span id="t2c_172" class="t s4_172">2) cT0–</span><span id="t2d_172" class="t s7_172">2, cN1 (single node ≤3 cm) </span>
<span id="t2e_172" class="t s4_172">3) cT0–2, cN1 (single node &gt;3 cm, or 2 or more ipsilateral nodes </span>
<span id="t2f_172" class="t s7_172">≤6 cm); or cT</span><span id="t2g_172" class="t s4_172">0–2, cN2; or cT3, cN0–2 </span>
<span id="t2h_172" class="t s4_172">4) cT4 or cN3 </span>
<span id="t2i_172" class="t s4_172">The algorithms for p16 (HPV)-positive oropharyngeal cancer in the NCCN </span>
<span id="t2j_172" class="t s4_172">Guidelines for Head and Neck Cancers incorporate the staging criteria </span>
<span id="t2k_172" class="t s4_172">presented in the 8 </span>
<span id="t2l_172" class="t s5_172">th </span>
<span id="t2m_172" class="t s4_172">Edition of the AJCC Cancer Staging Manual </span>
<span id="t2n_172" class="t s5_172">391 </span>
<span id="t2o_172" class="t s4_172">based </span>
<span id="t2p_172" class="t s4_172">on clinical staging criteria. This is to acknowledge that decision-making </span>
<span id="t2q_172" class="t s4_172">continues to be frequently based on data from trials that included </span>
<span id="t2r_172" class="t s4_172">oropharyngeal as well as other anatomic sites that were staged utilizing </span>
<span id="t2s_172" class="t s4_172">AJCC 7 </span>
<span id="t2t_172" class="t s5_172">th </span>
<span id="t2u_172" class="t s4_172">edition nodal staging criteria. </span>
<span id="t2v_172" class="t s5_172">390 </span>
<span id="t2w_172" class="t s9_172">Printed by Fredd Merc on 8/29/2024 4:45:54 AM. For personal use only. Not approved for distribution. Copyright © 2024 National Comprehensive Cancer Network, Inc., All Rights Reserved. </span></div>

</div>
</body>
</html>
